Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real
Aclarion (Nasdaq: ACON) said two abstracts on its Nociscan MR Spectroscopy platform were presented at the ASPN annual meeting. A real-world study workflow using Nociscan in 20 patients was described, and a case study reported 95% relief after basivertebral nerve ablation guided by Nociscan in a patient without classic Modic MRI changes.
How this was made
The 30-second read
Why it matters
The company is using ASPN abstracts to demonstrate expanding use cases for Nociscan, including integration into clinical workflow and potential to guide basivertebral nerve ablation even without classic Modic changes.
Market read
This is a promotional clinical-evidence update tied to conference presentations, likely supportive for sentiment but not a standalone catalyst like earnings, approvals, or contracts.
What to watch
Key missing items include sample size details beyond the planned 20-patient workflow, statistical outcomes, comparator performance versus standard MRI-only selection, and any payer or center adoption metrics.
Background
Aclarion’s Nociscan uses MR spectroscopy data and cloud-based signal processing to quantify disc biomarkers for chronic low back pain decision support.
Ticker impact
Aclarion announced two ASPN abstracts on Nociscan, including a real-world MRS workflow study and a BVNA case with 95% pain relief.
Near-term impact likely limited to sentiment, with follow-through only if later data or adoption metrics substantiate the claims.
The release provides preliminary real-world workflow results (20-patient design) and a single case study outcome, which can move biotech/health-tech sentiment but typically lacks the rigor of trial endpoints or approvals.
Market effects
Reinforces the broader narrative that MR spectroscopy and biomarker-driven decision support may expand in chronic low back pain care pathways.
No clear regional market linkage beyond US conference coverage.
Chronic low back pain is global, but the disclosed evidence is early and localized to specific clinical workflows/case reporting.
Counterpoint
Abstracts and case reports may overstate readiness for broad adoption; without controlled trial endpoints, investors may discount the signal.
Key entities
- companyAclarion, Inc.
Nasdaq-listed healthcare technology company developing Nociscan for chronic low back pain using MR spectroscopy and AI algorithms.
- productNociscan
SaaS platform that receives MRS data from MRI machines and outputs biomarker-based pain source probabilities.
- eventASPN Annual Meeting
Conference where the company presented two abstracts on Nociscan’s real-world workflow integration and BVNA application.
